| Added by | mollevi |
|---|---|
| Group name | EquipeMY |
| Item Type | Journal Article |
| Title | Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer |
| Creator | Lapeyre-Prost et al. |
| Author | Alexandra Lapeyre-Prost |
| Author | Marine Hug de Larauze |
| Author | Benoist Chibaudel |
| Author | Marie Line Garcia |
| Author | Veronique Guering-Meyer |
| Author | Olivier Bouché |
| Author | Eveline Boucher |
| Author | Marc Ychou |
| Author | Jérôme Dauba |
| Author | Stéphane Obled |
| Author | Astrid Lièvre |
| Author | David Malka |
| Author | Roger Faroux |
| Author | Isabelle Bonnet |
| Author | Julien Taieb |
| Author | Thierry André |
| Abstract | BACKGROUND: 5-Fluorouracil and leucovorin plus oxaliplatin (FOLFOX) or capecitabine plus oxaliplatin (XELOX) is a standard adjuvant treatment for patients with stage III colon cancer (CC). Capecitabine is an oral fluoropyrimidine, and administration of oxaliplatin does not necessarily require the insertion of a central venous access device (CVAD). We evaluated the feasibility of XELOX without a CVAD as adjuvant treatment in patients with stage III CC. PATIENTS AND METHODS: We retrospectively studied prospectively collected data from patients with stage III CC treated with XELOX in the International Duration Evaluation of Adjuvant Chemotherapy French trial. Patients were divided into 2 groups: those with a CVAD and those with peripheral venous access (PVA), including patients who had and had not had a CVAD at the first cycle of chemotherapy. Chemotherapy without a CVAD was considered feasible if the patient received all cycles of adjuvant therapy without it. RESULTS: A total of 203 patients were included: 86 (43%) in the PVA group and 116 (57%) in the CVAD group. Of the 85 patients in the PVA group (1 patient was not treated), 69 (81.2%) did not require the insertion of a CVAD. However, 16 (18.8%) required CVAD insertion owing to systematic delay of the initially planned CVAD before the second cycle of chemotherapy in 7, complications related to PVA usage in 5, a switch to the modified FOLFOX6 regimen in 2, and other reasons in 2. The oxaliplatin dose was similar in both groups regardless of the chemotherapy duration. XELOX without a CVAD was feasible for 81.2% of the patients for whom a CVAD had not been planned before chemotherapy and for 88.4% of patients for whom chemotherapy was planned without the use of a CVAD. CONCLUSION: XELOX chemotherapy without a CVAD is a feasible approach for treating patients with stage III CC in the adjuvant setting. |
| Publication | Clinical Colorectal Cancer |
| Volume | 15 |
| Issue | 3 |
| Pages | 250-256 |
| Date | 09 2016 |
| Journal Abbr | Clin Colorectal Cancer |
| Language | eng |
| DOI | 10.1016/j.clcc.2015.11.004 |
| ISSN | 1938-0674 |
| Library Catalog | PubMed |
| Extra | PMID: 26752558 |
| Tags | Adjuvant chemotherapy, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Central Venous Catheters, clinic, Colorectal Neoplasms, CVAD, Deoxycytidine, Disease-Free Survival, Feasibility Studies, Female, Fluorouracil, Humans, Male, Middle Aged, Neoplasm Staging, Peripheral venous access, Retrospective Studies, XELOX |
| Date Added | 2018/11/13 - 17:25:18 |
| Date Modified | 2019/05/21 - 14:44:46 |
Institut de Recherche en Cancérologie de
